FORA Capital LLC Has $280,000 Stake in TransMedics Group, Inc. $TMDX

Key Points

• FORA Capital LLC significantly reduced its stake in TransMedics Group by 85.5%, now holding only 4,161 shares after selling 24,514 shares in the first quarter, valued at approximately $280,000.
• Several institutional investors, including Braidwell LP and Dimensional Fund Advisors, made substantial increases to their holdings in TransMedics Group, showcasing growing institutional interest in the company.
• Analysts have revised their ratings and price targets for TransMedics Group, with a consensus rating of "Moderate Buy" and an average price target set at $123.00, following a strong quarterly earnings report that exceeded expectations.

FORA Capital LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 85.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,161 shares of the company's stock after selling 24,514 shares during the period. FORA Capital LLC's holdings in TransMedics Group were worth $280,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in TMDX. NBC Securities Inc. acquired a new position in shares of TransMedics Group in the 1st quarter valued at about $25,000. Smartleaf Asset Management LLC grew its stake in shares of TransMedics Group by 44.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares in the last quarter. Hager Investment Management Services LLC grew its stake in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after buying an additional 205 shares in the last quarter. CWM LLC grew its stake in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after buying an additional 155 shares in the last quarter. Finally, AlphaQuest LLC grew its stake in shares of TransMedics Group by 55.6% in the 1st quarter. AlphaQuest LLC now owns 1,288 shares of the company's stock valued at $87,000 after buying an additional 460 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Activity at TransMedics Group

In other news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Morgan Stanley boosted their price target on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Piper Sandler reissued an "overweight" rating and issued a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group boosted their price target on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Stock Performance

Shares of TMDX stock traded down $2.59 during trading hours on Wednesday, reaching $108.96. 571,643 shares of the company's stock were exchanged, compared to its average volume of 1,304,400. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $169.29. The stock has a market capitalization of $3.71 billion, a P/E ratio of 56.48 and a beta of 2.18. The business has a fifty day moving average price of $119.57 and a 200-day moving average price of $103.65. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same period in the previous year, the company earned $0.35 earnings per share. The company's quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.